Study identification

EU PAS number

EUPAS15418

Study ID

25369

Official title and acronym

Localised Neuropathic Pain (LNP) managed in the primary care setting in France, Ireland, Italy, Spain, and the United Kingdom: A cross-sectional study of prevalence, clinical characteristics, treatment patterns and patient’s reported outcomes

DARWIN EU® study

No

Study countries

France
Ireland
Italy
Spain
United Kingdom

Study description

Topical application of analgesics can offer a valid therapeutic alternative, providing Localised Neuropathic Pain (LNP) is recognised. To date only sparse data are available in literature about the features of LNP, its therapeutic management and its frequency in the primary care population in Europe. This study will attempt to fill such a knowledge gap in the primary care population of five EU countries, namely France, Ireland, Italy, Spain and the United Kingdom. Data on the frequency of LNP and the clinical profile of patients showing signs and symptoms of LNP, their current treatment patterns, and patient’s reported health status, including quality of sleep, can help to identify unmet medical needs in such a problematic therapeutic area.

Study status

Finalised
Research institutions and networks

Institutions

OXON Epidemiology
Spain
United Kingdom
First published:
15/03/2024
Institution Laboratory/Research/Testing facility Non-Pharmaceutical company ENCePP partner
National Institue for Health Research (UK),Multiple centres: 50 centres are involved in the study

Contact details

Nawab Qizilbash

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Grunenthal GmbH
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable